Tech reviews

Precision BioSciences (NASDAQ:DTIL) versus Acorda Therapeutics (NASDAQ:ACOR) Financial Review


Precision BioSciences (NASDAQ:DTIL) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Earnings and Valuation

This table compares Precision BioSciences and Acorda Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precision BioSciences $10.88 million 46.36 -$46.04 million N/A N/A
Acorda Therapeutics $471.43 million 0.21 $33.68 million $1.82 1.15

Acorda Therapeutics has higher revenue and earnings than Precision BioSciences.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Precision BioSciences and Acorda Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences 6 3.00
Acorda Therapeutics 1 5 1 2.00

Precision BioSciences currently has a consensus target price of $22.80, indicating a potential upside of 129.61%. Acorda Therapeutics has a consensus target price of $7.07, indicating a potential upside of 236.51%. Given Acorda Therapeutics’ higher possible upside, analysts plainly believe Acorda Therapeutics is more favorable than Precision BioSciences.

Institutional & Insider Ownership

42.9% of Precision BioSciences shares are owned by institutional investors. 7.1% of Acorda Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Precision BioSciences and Acorda Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precision BioSciences -423.14% -78.51% -35.67%
Acorda Therapeutics -155.89% -12.96% -5.63%

Summary

Acorda Therapeutics beats Precision BioSciences on 7 of the 11 factors compared between the two stocks.

About Precision BioSciences

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

About Acorda Therapeutics

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson’s disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson’s disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.



Receive News & Ratings for Precision BioSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Precision BioSciences and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

READ  Samsung Galaxy M51 review – insane battery life

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.